

26 April 2023

Nivolumab

Seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

- Ipilimumab (monotherapy) <5
- Nivolumab (monotherapy) <5
- Nivolumab AND Ipilimumab (combination) 5
- Pembrolizumab 24
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib 5 /Encorafenib AND Binimetinib /Trametinib /Vemurafenib / Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy <5

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?

- Nivolumab (monotherapy) <5
- Nivolumab + Ipilimumab <5
- Nivolumab + Cabozantinib <5
- Avelumab + Axitinib <5

3. In the past 3 months, how many patients have been initiated* on the following agents for treatment of Oesophageal Cancer:

- Nivolumab monotherapy or in combination with Ipilimumab <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.